Landos Biopharma IncNASDAQ LABP Stock Report

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The company is headquartered in Blacksburg, Virginia and currently employs 46 full-time employees. The company went IPO on 2021-02-04. The firm through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that target mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. The firm has identified approximately seven immunometabolic pathways or targets. The company is focused on its clinical-stage programs, including omilancor for the treatment of ulcerative colitis (UC), NX-13 for the treatment of UC and LABP-104 for the potential treatment of systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).